Glaxosmithkline Research & Development Limited

• Phase 3 study of belantamab mafodotin, lenalidomide, and dexamethasone (BRd) versus daratumumab, lenalidomide, and dexamethasone (DRd) in pa… Recruiting
  2024-516030-35-00 Phase III 11 countries BELANTAMAB MAFODOTIN; DARATUMUMAB; DEXAMETHASONE; DEXAMETHASONE PH. EUR.; LENALI…
• A study describing the efficacy and safety of belimumab administered subcutaneously in adult participants with early systemic lupus erythema… Recruiting
  2023-509146-35-00 Phase IV 6 countries BELIMUMAB
• A study to investigate the safety and efficacy of GSK4532990 compared with placebo in adult participants aged 18 to 70 years with alcohol-re… Recruiting
  2024-511596-15-00 Phase II 8 countries
• A Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Clinical Activity of GSK5733584 for Injection in Subject… Recruiting
  2024-513860-25-00 Phase I/II 8 countries
• A Phase 2, open label, randomized study of neoadjuvant dostarlimab plus CAPEOX versus CAPEOX in participants with previously untreated T4N0 … Recruiting
  2024-513441-36-00 Phase II 3 countries CAPECITABINE; DOSTARLIMAB; OXALIPLATIN
• A Phase 3 study of Dostarlimab as Sequential Therapy after Chemoradiation compared to placebo in adult participants with Locally Advanced Un… Recruiting
  2023-508613-17-00 Phase III 13 countries DOSTARLIMAB
• A study of the efficacy and safety of belimumab compared to placebo in adults with systemic sclerosis-associated interstitial lung disease. Recruiting
  2023-503219-14-01 Phase II/III 8 countries BELIMUMAB
• A study to investigate the safety and clinical activity of belantamab for the treatment of multiple myeloma when used as monotherapy and in … Recruiting
  2022-501941-63-00 Phase I (FiH) 6 countries
• A study to Investigate the efficacy and safety of Depemokimab compared with placebo in Adults with Hypereosinophilic Syndrome (HES) Recruiting
  2023-510346-25-00 Phase III 9 countries DEPEMOKIMAB
• EXTENSION STUDY FOR PATIENTS WHO HAVE COMPLETED A PRIOR GLAXOSMITHKLINE/TESARO-SPONSORED NIRAPARIB STUDY AND ARE JUDGED BY THE INVESTIGATOR … Recruiting
  2023-506618-29-00 Phase II 6 countries NIRAPARIB TOSILATE MONOHYDRATE
• FTIH study to investigate the safety and preliminary efficacy of the DNA-repair inhibitor GSK4418959 alone or in combination with other anti… Ended
  2024-519721-37-00 Phase I (FiH) 3 countries DOSTARLIMAB; GSK4418959A
• A dose finding study with an anti-TSLP antibody (GSK5784283) in adults aged 18 to 75 years of age with uncontrolled asthma. Ended
  2024-518321-15-00 Phase II 5 countries GSK5784283
• A study for GSK3862995B in healthy participants and participants with Chronic Obstructive Pulmonary Disease Ended
  2023-506880-32-01 Phase I 1 country
• A Multicenter, Randomized, Double-Blind, Placebo-controlled Study to Assess the Efficacy and Safety of Treatment with Bepirovirsen in Partic… Ended
  2023-509588-25-00 Phase II 3 countries BEPIROVIRSEN SODIUM
• A Phase 3 study of belrestotug plus dostarlimab compared with placebo plus pembrolizumab in previously untreated PD L1 high NSCLC Ended
  2023-504753-12-00 Phase III 20 countries DOSTARLIMAB; HUMAN IGG1 KAPPA MONOCLONAL ANTIBODY AGAINST TIGIT; PEMBROLIZUMAB
• REIMAGINE – Real-world EvaluatIon of Mepolizumab in severe Asthma achievinG on treatment clinIcal remissioN, a prospEctive study. Ended
  2023-509026-21-00 Phase IV 6 countries MEPOLIZUMAB
• Phase 2 Platform Study of Novel Immunotherapy Combinations as First-Line Treatment in Participants with PD-L1 Positive Recurrent/Metastatic … Ended
  2023-503428-24-00 Phase II 12 countries DOSTARLIMAB; GSK4381562A; GSK6097608; HUMAN IGG1 KAPPA MONOCLONAL ANTIBODY AGAIN…
• Phase 3 study of perioperative dostarlimab in participants with untreated T4N0 or stage III dMMR/MSI-H resectable colon cancer Ended
  2023-503265-27-00 Phase III 14 countries CAPECITABINE; DOSTARLIMAB; FLUOROURACIL; FOLINIC ACID; OXALIPLATIN
• A Phase 1 First-Time-in-Human, Open-Label Study of GSK4381562 Administered as Monotherapy and in Combination with Anticancer Agents in Parti… Ended
  2023-509414-11-00 Phase I 2 countries
• Phase 2 Study of Dostarlimab in Untreated dMMR/MSI-H Locally Advanced Rectal Cancer Ended
  2023-509583-22-00 Phase II 5 countries DOSTARLIMAB
• PH2a, Platform Study of Novel Immunotherapy Combinations in Participants with Previously Untreated, Advanced/Metastatic NSCLC Ended
  2023-505057-40-00 Phase II 11 countries DOSTARLIMAB; GSK6097608; HUMAN IGG1 KAPPA MONOCLONAL ANTIBODY AGAINST TIGIT; PEM…
• A study to investigate the efficacy and safety of depemokimab compared with mepolizumab in adults with relapsing or refractory Eosinophilic … Ended
  2023-510019-20-00 Phase III 11 countries DEPEMOKIMAB
• Long-term follow-up study to evaluate durability of treatment response in previous bepirovirsen study participants (B-Sure). Ended
  2023-506867-33-01 Phase II 9 countries BEPIROVIRSEN
• A Phase I Study of Belantamab Mafodotin in Multiple Myeloma Participants with Normal and Impaired Renal Function Ended
  2023-506063-34-00 Phase I (Other) 1 country

Showing 25–48 of 89 trials